PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications

BACKGROUND: Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hae-Yun, Kim, Tae Ho, Lee, Jong-Eun, Kim, Hong Kwan, Cho, Jong Ho, Choi, Yong Soo, Shin, Sumin, Lee, Se-Hoon, Rhee, Hwanseok, Lee, Hee Kyung, Choi, Hyun Jung, Jang, Hye Yoon, Lee, Seungjae, Kang, Jung Hee, Choi, Young Ae, Lee, Sanghyuk, Lee, Jinseon, Choi, Yoon La, Kim, Jhingook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409653/
https://www.ncbi.nlm.nih.gov/pubmed/32762722
http://dx.doi.org/10.1186/s12967-020-02473-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409653/
https://www.ncbi.nlm.nih.gov/pubmed/32762722
http://dx.doi.org/10.1186/s12967-020-02473-y

Ejemplares similares